BRISTOL-MYERS SQUIBB COMPANY Recognition of Deferred Revenue
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Recognition of Deferred Revenue of $16.00 million for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-10-25.
Discontinued › Income Statement › Other Income
us-gaap:RecognitionOfDeferredRevenue · last filed 2018-10-25
- BRISTOL-MYERS SQUIBB COMPANY recognition of deferred revenue for the quarter ending 2018-09-30 was $16.00M, a 20.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY recognition of deferred revenue for the quarter ending 2018-06-30 was $16.00M, a 15.79% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY recognition of deferred revenue for the quarter ending 2018-03-31 was $16.00M, a 20.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY recognition of deferred revenue for the quarter ending 2017-09-30 was $20.00M, a 60.00% decline year-over-year.
| Period end | Recognition of Deferred Revenue 3 month | Recognition of Deferred Revenue 6 month | Recognition of Deferred Revenue 9 month |
|---|---|---|---|
| 2018-09-30 | $16.00M 10-Q · filed 2018-10-25 | $32.00M derived: sum of 2 quarters · filed 2018-10-25 | $48.00M 10-Q · filed 2018-10-25 |
| 2018-06-30 | $16.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $32.00M 10-Q · filed 2018-07-26 | |
| 2018-03-31 | $16.00M 10-Q · filed 2018-04-26 | ||
| 2017-09-30 | $20.00M 10-Q · filed 2018-10-25 | $39.00M derived: sum of 2 quarters · filed 2018-10-25 | $59.00M 10-Q · filed 2018-10-25 |
| 2017-06-30 | $19.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $39.00M 10-Q · filed 2018-07-26 | |
| 2017-03-31 | $20.00M 10-Q · filed 2018-04-26 | ||
| 2016-09-30 | $50.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-26 | $111.00M derived: sum of 2 quarters · filed 2017-10-26 | $193.00M 10-Q · filed 2017-10-26 |
| 2016-06-30 | $61.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-27 | $143.00M 10-Q · filed 2017-07-27 | |
| 2016-03-31 | $82.00M 10-Q · filed 2017-04-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |